Back to top

Analyst Blog

Repros Therapeutics Inc.’s (RPRX - Snapshot Report) share price has been on a declining trend ever since the company received guidance from the U.S. Food and Drug Administration (FDA) related to the Androxal development program on Oct 22, 2013. In view of the guidance, Repros now expects to submit the new drug application (NDA) to the FDA in the fourth quarter of 2014. Earlier, the company had planned on submitting the NDA in mid-2014 with potential launch in 2015.

Investors reacted negatively to the delay in the potential approval of Repros. The stock price of Repros fell significantly since then. Overall, the stock lost 35.5% since the announcement. The release of the third quarter 2013 results did not revive investor confidence in the stock with barely any reversal in trends.

Repros reported third quarter 2013 loss of 26 cents per share, narrower than the year-ago loss of 30 cents per share and the Zacks Consensus Estimate of loss of 33 cents. The narrower loss was due to an increase in the number of shares.

The company’s revenue for the third quarter of 2013 was $0.3 million as compared to $0.1 million in the year-ago period. The entire revenues came from interest income.

In the third quarter of 2013, general and administrative expenses decreased 16% to $1.2 million due to lower stock based compensation. Research and development expenses shot up 53% year over year to $4.8 million, reflecting higher pipeline investment.

Androxal, the advanced pipeline candidate at Repros, is being evaluated for the treatment of secondary hypogonadism. Currently prescribed therapies for secondary hypogonadism include AbbVie Inc.’s (ABBV - Analyst Report) AndroGel.

On Jun 25, 2013, the company completed a public offering of 4,312,500 shares at a price of $19.00 per share. Net proceeds from the transaction, approximately $76.8 million, boosted Repros’ cash balance which jumped to $81.8 million in Sep 30, 2013 from $24.2 in Dec 31, 2012.

Repros currently carries a Zacks Rank #3 (Hold). We expect investor focus to remain on Androxal updates.

However, companies like Actelion Ltd. (ALIOF) and AMAG Pharmaceuticals Inc. (AMAG - Snapshot Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 116.37 +7.72%
CHYRONHEGO… CHYR 2.72 +5.84%
US SILICA H… SLCA 70.72 +4.00%
MALLINCKROD… MNK 80.11 +2.32%
RF MICRO DE… RFMD 11.76 +2.31%